Novo Nordisk broke ground on its new 2 billion US dollar production facility in Clayton, North Carolina.
The facility will produce active pharmaceutical ingredients (API) for a range of Novo Nordisk's current and future GLP-1 and insulin products. Once fully operational in 2020, Clayton will ensure production capacity for diabetes care products in the US for the decade ahead.
The new site is situated adjacent to Novo Nordisk's existing 42,000 m2 facility which assembles and packages FlexPen® and FlexTouch® prefilled insulin devices for the US market. The expansion is expected to create close to 700 new jobs and Novo Nordisk expects to create a significant employment effect during the construction period with up to 2,500 people working on the project at its peak.
|Clayton, North Carolina
|New Production Facility
|Jobs to be created